A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells
Open Access
- 6 December 2011
- journal article
- research article
- Published by Wiley in International Journal of Peptides
- Vol. 2012, 1-6
Abstract
Recent studies have highlighted the AT1 receptor as a potential therapeutic target in breast cancer, while the role of the AT2 subtype in this disease has remained largely neglected. The present study describes the generation and characterization of a new cellular model of human invasive breast cancer cells (D3H2LN-AT2) stably expressing high levels of Flag-tagged human AT2 receptor (Flag-hAT2). These cells exhibit high-affinity binding sites for AngII, and total binding can be displaced by the AT2-selective antagonist PD123319 but not by the AT1-selective antagonist losartan. Of interest, high levels of expression of luciferase and green fluorescent protein make these cells suitable for bioluminescence and fluorescence studies in vitro and in vivo. We provide here a novel tool to investigate the AT2 receptor functions in breast cancer cells, independently of AT1 receptor activation.Keywords
This publication has 35 references indexed in Scilit:
- New insights into angiotensin receptor actions: from blood pressure to agingCurrent Opinion in Nephrology and Hypertension, 2011
- Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?British Journal of Cancer, 2010
- Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic miceBMC Cancer, 2010
- Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological TherapyAnnual Review of Pharmacology and Toxicology, 2010
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistProceedings of the National Academy of Sciences, 2009
- Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosisBritish Journal of Cancer, 2008
- Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesisLaboratory Investigation, 2007
- AT2 Receptor Stimulation May Halt Progression of PheochromocytomaAnnals of the New York Academy of Sciences, 2006
- Expression of Pitx2 in stromal cells is required for normal hematopoiesisBlood, 2006
- Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasisBiochemical and Biophysical Research Communications, 2002